Abstract
Background: Community-acquired pneumonia (CAP) in young children may involve systemic inflammation, coagulation activation, fibrin turnover, and endothelial activation. The extent to which hemostatic markers are associated with complicated CAP independently of clinical severity remains uncertain.
Objective: To compare the hemostatic profile of children aged 2 months to 3 years with complicated and uncomplicated CAP and healthy controls, and to assess severity-adjusted associations and exploratory discriminatory performance.
Methods: In this prospective observational cohort with a cross-sectional biomarker assessment at admission, 131 hospitalized children with CAP (99 complicated and 32 uncomplicated) and 30 healthy controls were studied. Activated partial thromboplastin time (aPTT), thrombin time (TT), prothrombin time (PT), international normalized ratio (INR), fibrinogen, soluble fibrin monomer complexes (SFMC), D-dimer, and von Willebrand factor antigen (vWF:Ag) were measured within 24 hours of admission. Group comparisons used Kruskal–Wallis and Dunn tests with Bonferroni correction. Severity-adjusted associations were estimated using Firth penalized logistic regression. Exploratory receiver operating characteristic (ROC) analyses underwent 1,000-replicate bootstrap internal validation.
Results: All eight markers differed across the three groups (overall p<0.001). Median SFMC concentrations were 20.16 versus 2.95 mg/100 mL, D-dimer 6.56 versus 0.29 µg FEU/mL, and vWF:Ag 261 versus 101 IU/dL in complicated CAP and controls, respectively. SFMC and D-dimer were also elevated in uncomplicated CAP relative to controls (adjusted p<0.001). In severity-adjusted regression, vWF:Ag remained associated with complicated CAP (odds ratio [OR] per 10 IU/dL, 2.49; 95% confidence interval [CI], 1.51–4.09; p<0.001); the D-dimer association was imprecise (OR per 1 µg FEU/mL, 2.09; 95% CI, 0.89–4.90; p=0.089). Exploratory areas under the ROC curve (AUCs) were 0.952 for vWF:Ag, 0.886 for aPTT, and 0.812 for D-dimer.
Conclusions: Complicated CAP in young children was associated with broader hemostatic alterations than uncomplicated CAP. vWF:Ag provided severity-adjusted information in this cohort, but discriminatory estimates and derived thresholds require external validation before clinical use.
References
McAllister DA, Liu L, Shi T, et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis. Lancet Glob Health. 2019;7(1):e47-e57. doi:10.1016/S2214-109X(18)30408-X.
Fischer Walker CL, Rudan I, Liu L, et al. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381(9875):1405-1416. doi:10.1016/S0140-6736(13)60222-6.
Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372(9):835-845. doi:10.1056/NEJMoa1405870.
Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25-e76. doi:10.1093/cid/cir531.
de Benedictis FM, Kerem E, Chang AB, Colin AA, Zar HJ, Bush A. Complicated pneumonia in children. Lancet. 2020;396(10253):786-798. doi:10.1016/S0140-6736(20)31550-6.
Haq IJ, Battersby AC, Eastham K, McKean M. Community acquired pneumonia in children. BMJ. 2017;356:j686. doi:10.1136/bmj.j686.
Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66 Suppl 2:ii1-ii23. doi:10.1136/thoraxjnl-2011-200598.
Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38(2 Suppl):S26-S34. doi:10.1097/CCM.0b013e3181c98d21.
Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38-44. doi:10.1016/j.thromres.2016.11.007.
van der Poll T, de Boer JD, Levi M. The effect of inflammation on coagulation and vice versa. Curr Opin Infect Dis. 2011;24(3):273-278. doi:10.1097/QCO.0b013e328344c078.
van der Poll T, Levi M. Crosstalk between inflammation and coagulation: the lessons of sepsis. Curr Vasc Pharmacol. 2012;10(5):632-638. doi:10.2174/157016112801784549.
Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost. 2013;39(5):559-566. doi:10.1055/s-0033-1343894.
Levi M, van der Poll T. Coagulation in patients with severe sepsis. Semin Thromb Hemost. 2015;41(1):9-15. doi:10.1055/s-0034-1398376.
Song J, Li N, Li R, Xu Y. Clinical value of coagulation function indicators in children with severe pneumonia. Int J Gen Med. 2024;17:4659-4668. doi:10.2147/IJGM.S478443.
Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989-1994. doi:10.1111/jth.14578.
Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost. 2020;46(1):89-95. doi:10.1055/s-0039-1694995.
Levi M, Schultz M, van der Poll T. Disseminated intravascular coagulation in infectious disease. Semin Thromb Hemost. 2010;36(4):367-377. doi:10.1055/s-0030-1254046.
Chen J, Chung DW. Inflammation, von Willebrand factor, and ADAMTS13. Blood. 2018;132(2):141-147. doi:10.1182/blood-2018-02-769000.
O'Donnell J, Laffan MA. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med. 2001;11(4):343-351. doi:10.1046/j.1365-3148.2001.00315.x.
O'Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol. 2002;22(2):335-341. doi:10.1161/hq0202.103997.
Franchini M, Capra F, Targher G, Montagnana M, Lippi G. Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thromb J. 2007;5:14. doi:10.1186/1477-9560-5-14.
Green GH, Diggle PJ. On the operational characteristics of the Benjamini and Hochberg false discovery rate procedure. Stat Appl Genet Mol Biol. 2007;6:Article27. doi:10.2202/1544-6115.1302.
Puhr R, Heinze G, Nold M, Lusa L, Geroldinger A. Firth’s logistic regression with rare events: accurate effect estimates and predictions? Stat Med. 2017;36(14):2302-2317. doi:10.1002/sim.7273.
Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014;35(29):1925-1931. doi:10.1093/eurheartj/ehu207.
Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54(8):774-781. doi:10.1016/S0895-4356(01)00341-9.
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-845. PMID:3203132.
Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-35. PMID:15405679.
Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162(1):55-63. doi:10.7326/M14-0697.
Binuya MAE, Engelhardt EG, Schats W, Schmidt MK, Steyerberg EW. Methodological guidance for the evaluation and updating of clinical prediction models: a systematic review. BMC Med Res Methodol. 2022;22(1):316. doi:10.1186/s12874-022-01801-8.
Yang C, Zeng HH, Huang J, Zhang QY, Lin K. Predictive roles of D-dimer for mortality of patients with community-acquired pneumonia: a systematic review and meta-analysis. J Bras Pneumol. 2021;47(6):e20210072. doi:10.36416/1806-3756/e20210072.
Snijders D, Schoorl M, Schoorl M, Bartels PC, van der Werf TS, Boersma WG. D-dimer levels in assessing severity and clinical outcome in patients with community-acquired pneumonia: a secondary analysis of a randomised clinical trial. Eur J Intern Med. 2012;23(5):436-441. doi:10.1016/j.ejim.2011.10.019.
Cerda-Mancillas MC, Santiago-Germán D, Andrade-Bravo B, et al. D-dimer as a biomarker of severity and adverse outcomes in patients with community acquired pneumonia. Arch Med Res. 2020;51(5):429-435. doi:10.1016/j.arcmed.2020.04.014.
Nastasijević Borovac D, Radjenović Petković T, Pejčić T, et al. Role of D-dimer in predicting mortality in patients with community-acquired pneumonia. Med Glas (Zenica). 2014;11(1):37-43. PMID:24496339.
Ge YL, Liu CH, Wang N, et al. Elevated plasma D-dimer in adult community-acquired pneumonia patients is associated with an increased inflammatory reaction and lower survival. Clin Lab. 2019;65(1). doi:10.7754/Clin.Lab.2018.180720.
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. doi:10.1371/journal.pmed.0040296.